Repurposing Lithium for Parkinson's Disease: a RCT - Trial NCT06339034
Access comprehensive clinical trial information for NCT06339034 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by State University of New York at Buffalo and is currently Not yet recruiting. The study focuses on Parkinson Disease. Target enrollment is 20 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
State University of New York at Buffalo
Timeline & Enrollment
Phase 1/2
Jun 01, 2024
Oct 01, 2025
Primary Outcome
MRI-derived free water (FW) levels.,Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression,Serum neurofilament light chain (NfL)
Summary
This study will examine the effects of lithium 20mg/day compared to placebo on MRI and
 blood-based biomarkers among 20 early-stage Parkinson's disease patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06339034
Non-Device Trial